We would like to kindly inform you on our plans to adjust Company’s organizational structure to comply with all the conditional regulatory requirements necessary to be met prompting going public via a debut on the NewConnect Stock Exchange market by the end of 2020. Genomtec has concluded this decision being based on observations of how the Polish capital market has changed in the recent years. It seems that the Polish Stock Exchange is maturing, and innovative projects – such as Genomtec ID – are often more noticeable and prised by Polish investors, partially due to offering potentially higher investment returns for their shareholders (as compared to standard savings and investment instruments). Moreover, the current market and public environment is favourable towards development of the diagnostic devices. Our goal is to obtain further funding for the development and commercialization of the Company’s flagship solution, the mobile genetic diagnostic platform Genomtec ID. Not without notice is the fact of commercialization of a rapid laboratory genetic test for the detection of SARS-CoV-2 virus, which subsidises further R&D works. Our partner in the process of entering the NewConnect Stock Exchange market is INC Group, inclusive of their Brokerage House INC that will be actively managing shares’ book-building and their issue.